{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T20:11:11Z","timestamp":1778011871123,"version":"3.51.4"},"reference-count":24,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T00:00:00Z","timestamp":1777939200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"DOI":"10.13039\/501100004433","name":"Chinese Pharmaceutical Association Hospital Pharmacy department","doi-asserted-by":"publisher","award":["CPA-Z05-ZC-2021-002"],"award-info":[{"award-number":["CPA-Z05-ZC-2021-002"]}],"id":[{"id":"10.13039\/501100004433","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82204507"],"award-info":[{"award-number":["82204507"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000265","name":"UK Medical Research Council","doi-asserted-by":"publisher","award":["MR\/M008665\/1"],"award-info":[{"award-number":["MR\/M008665\/1"]}],"id":[{"id":"10.13039\/501100000265","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Special Research Project Research on High-Quality Development of Hospitals and Pharmaceutical Innovation","award":["2024-PJZXKT-07"],"award-info":[{"award-number":["2024-PJZXKT-07"]}]},{"name":"National Pharmaceutical Service Research Project \u201cJu huo You cai\u201d","award":["CMEAPC2024004"],"award-info":[{"award-number":["CMEAPC2024004"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,5,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background and Objectives<\/jats:title>\n                    <jats:p>Tigecycline is not usually recommended for patients under 18\u2005years due to limited safety data and adverse events, and dosing guidelines for children under 8 remain undefined. However, it remains a critical treatment option for life-threatening multidrug-resistant infections in critically ill children. This study aimed to characterize the population pharmacokinetics (PopPK) of tigecycline in children, identify key covariates affecting PK variability and propose optimized dosing regimens tailored to specific infection types.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Materials and methods<\/jats:title>\n                    <jats:p>This study enrolled 20 children receiving intravenous tigecycline. One- and two-compartment models were explored. Monte Carlo simulations with age-stratified tigecycline dosing regimens were performed to evaluate the probability of target attainment (PTA) for various dosing regimens.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A two-compartment model incorporating allometric scaling and a sigmoidal maturation function best described tigecycline PK. PTA analyses indicated that the standard dose was sufficient for children with infections caused by susceptible Streptococcus groups (breakpoint 0.125\u2005mg\/L) across community-acquired pneumonia (CAP), complicated intra-abdominal infections (cIAI) and complicated skin and skin structure infections (cSSSI). For susceptible Enterobacterales, Staphylococcus spp. or Enterococcus spp. (breakpoint 0.5\u2005mg\/L), the standard dose reached PK\/pharmacodynamic (PD) targets for CAP, while cIAI required twice the standard dose. cSSSI necessitated higher dosing (150\u2005mg) in adolescents; however, potential toxicity concerns necessitate extreme caution with such escalation. Infections caused by Enterobacteriaceae with intermediate resistance (breakpoint 4\u2005mg\/L) failed to achieve PK\/PD targets even with increased doses exceeding 4.8\u2005mg\/kg.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Overall, these results suggest that current dosing recommendations may be insufficient for less susceptible pathogens.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/jac\/dkag156","type":"journal-article","created":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T11:30:14Z","timestamp":1776771014000},"source":"Crossref","is-referenced-by-count":0,"title":["Population pharmacokinetics and probability of target attainment of tigecycline in critically ill children"],"prefix":"10.1093","volume":"81","author":[{"given":"Wenjuan","family":"Hu","sequence":"first","affiliation":[{"name":"Department of Pharmacy, Shanghai Children\u2019s Hospital, School of Medicine, Shanghai Jiao Tong University , Shanghai ,","place":["China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yawen","family":"Yuan","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy, Shanghai Children\u2019s Medical Center, School of Medicine, Shanghai Jiao Tong University , Shanghai 200127 ,","place":["China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Boyu","family":"Tan","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Shanghai Children\u2019s Hospital, School of Medicine, Shanghai Jiao Tong University , Shanghai ,","place":["China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qiaoling","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Shanghai Children\u2019s Hospital, School of Medicine, Shanghai Jiao Tong University , Shanghai ,","place":["China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuelian","family":"Jiang","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy, Shanghai Children\u2019s Medical Center, School of Medicine, Shanghai Jiao Tong University , Shanghai 200127 ,","place":["China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yijun","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Shanghai Children\u2019s Hospital, School of Medicine, Shanghai Jiao Tong University , Shanghai ,","place":["China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Huajun","family":"Sun","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Shanghai Children\u2019s Hospital, School of Medicine, Shanghai Jiao Tong University , Shanghai ,","place":["China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhiling","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy, Shanghai Children\u2019s Medical Center, School of Medicine, Shanghai Jiao Tong University , Shanghai 200127 ,","place":["China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yun","family":"Cui","sequence":"additional","affiliation":[{"name":"Department of Critical Care Medicine, Shanghai Children\u2019s Hospital, School of Medicine, Shanghai Jiao Tong University , Shanghai ,","place":["China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4561-7173","authenticated-orcid":false,"given":"Joseph F","family":"Standing","sequence":"additional","affiliation":[{"name":"Infection, Immunity, Inflammation Section, UCL Institute of Child Health , 30 Guilford Street, London WC1N 1EH ,","place":["UK"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2026,5,5]]},"reference":[{"key":"2026050515301343200_dkag156-B1","doi-asserted-by":"publisher","first-page":"783","DOI":"10.3390\/biom14070783","article-title":"Third-generation tetracyclines: current knowledge and therapeutic potential","volume":"14","author":"Kounatidis","year":"2024","journal-title":"Biomolecules"},{"key":"2026050515301343200_dkag156-B2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00854-21","article-title":"Tigecycline-induced tooth discoloration in children younger than eight years","volume":"65","author":"Zhu","year":"2021","journal-title":"Antimicrob Agents Chemother"},{"key":"2026050515301343200_dkag156-B3","doi-asserted-by":"publisher","first-page":"R90","DOI":"10.1186\/cc13858","article-title":"High dose tigecycline in critically ill patients with severe infections due to multidrug-resistant bacteria","volume":"18","author":"De Pascale","year":"2014","journal-title":"Crit Care"},{"key":"2026050515301343200_dkag156-B4","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1007\/s00228-020-02998-7","article-title":"Monte Carlo simulation evaluation of tigecycline dosing for bacteria with raised minimum inhibitory concentrations in non-critically ill adults","volume":"77","author":"Kispal","year":"2021","journal-title":"Eur J Clin Pharmacol"},{"key":"2026050515301343200_dkag156-B5","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2023.1083464","article-title":"Population pharmacokinetics of tigecycline in critically ill patients","volume":"14","author":"Luo","year":"2023","journal-title":"Front Pharmacol"},{"key":"2026050515301343200_dkag156-B6","doi-asserted-by":"publisher","first-page":"2838","DOI":"10.1111\/bcp.14692","article-title":"Population pharmacokinetics and exposure-response analysis of tigecycline in patients with hospital-acquired pneumonia","volume":"87","author":"Zhou","year":"2021","journal-title":"Br J Clin Pharmacol"},{"key":"2026050515301343200_dkag156-B7","doi-asserted-by":"publisher","first-page":"1365","DOI":"10.1093\/jac\/dkac036","article-title":"Tigecycline population pharmacokinetics in critically ill patients with decompensated cirrhosis and severe infections","volume":"77","author":"Bastida","year":"2022","journal-title":"J Antimicrob Chemother"},{"key":"2026050515301343200_dkag156-B8","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00345-17","article-title":"Population pharmacokinetics of tigecycline in critically ill patients with severe infections","volume":"61","author":"Xie","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"2026050515301343200_dkag156-B9","doi-asserted-by":"publisher","first-page":"1756","DOI":"10.1128\/AAC.01232-12","article-title":"Randomized phase 2 trial to evaluate the clinical efficacy of two high-dosage tigecycline regimens versus imipenem-cilastatin for treatment of hospital-acquired pneumonia","volume":"57","author":"Ramirez","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"2026050515301343200_dkag156-B10","doi-asserted-by":"publisher","first-page":"1939","DOI":"10.1128\/AAC.01084-06","article-title":"Exposure-response analyses of tigecycline efficacy in patients with complicated skin and skin-structure infections","volume":"51","author":"Meagher","year":"2007","journal-title":"Antimicrob Agents Chemother"},{"key":"2026050515301343200_dkag156-B11","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1128\/AAC.00813-07","article-title":"Exposure-response analyses of tigecycline efficacy in patients with complicated intra-abdominal infections","volume":"52","author":"Passarell","year":"2008","journal-title":"Antimicrob Agents Chemother"},{"key":"2026050515301343200_dkag156-B12","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.1128\/AAC.01615-10","article-title":"Pharmacological and patient-specific response determinants in patients with hospital-acquired pneumonia treated with tigecycline","volume":"56","author":"Bhavnani","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"2026050515301343200_dkag156-B13","doi-asserted-by":"publisher","first-page":"676","DOI":"10.3390\/antibiotics9100676","article-title":"Some suggestions from PK\/PD principles to contain resistance in the clinical setting-focus on ICU patients and Gram-negative strains","volume":"9","author":"Adembri","year":"2020","journal-title":"Antibiotics (Basel)"},{"key":"2026050515301343200_dkag156-B14","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1111\/bcp.13119","article-title":"Understanding and applying pharmacometric modelling and simulation in clinical practice and research","volume":"83","author":"Standing","year":"2017","journal-title":"Br J Clin Pharmacol"},{"key":"2026050515301343200_dkag156-B15","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1007\/s00467-008-0997-5","article-title":"Human renal function maturation: a quantitative description using weight and postmenstrual age","volume":"24","author":"Rhodin","year":"2009","journal-title":"Pediatr Nephrol"},{"key":"2026050515301343200_dkag156-B16","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1177\/2168479019856572","article-title":"Pediatric age groups and approach to studies","volume":"53","author":"Job","year":"2019","journal-title":"Ther Innov Regul Sci"},{"key":"2026050515301343200_dkag156-B17","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1186\/s13054-018-2278-4","article-title":"Tigecycline in critically ill patients on continuous renal replacement therapy: a population pharmacokinetic study","volume":"22","author":"Broeker","year":"2018","journal-title":"Crit Care"},{"key":"2026050515301343200_dkag156-B18","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02273-17","article-title":"Population pharmacokinetics of high-dose tigecycline in patients with sepsis or septic shock","volume":"62","author":"Borsuk-De Moor","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"2026050515301343200_dkag156-B19","doi-asserted-by":"publisher","first-page":"3701","DOI":"10.1128\/AAC.01636-05","article-title":"Population pharmacokinetics of tigecycline in patients with complicated intra-abdominal or skin and skin structure infections","volume":"50","author":"Van Wart","year":"2006","journal-title":"Antimicrob Agents Chemother"},{"key":"2026050515301343200_dkag156-B20","doi-asserted-by":"publisher","first-page":"5180","DOI":"10.1128\/AAC.01414-09","article-title":"Tigecycline population pharmacokinetics in patients with community- or hospital-acquired pneumonia","volume":"54","author":"Rubino","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"key":"2026050515301343200_dkag156-B21","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2024.1342947","article-title":"Population pharmacokinetics and individualized dosing of tigecycline for critically ill patients: a prospective study with intensive sampling","volume":"15","author":"Su","year":"2024","journal-title":"Front Pharmacol"},{"key":"2026050515301343200_dkag156-B22","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1111\/bcp.13160","article-title":"Scaling clearance in paediatric pharmacokinetics: all models are wrong, which are useful?","volume":"83","author":"Germovsek","year":"2017","journal-title":"Br J Clin Pharmacol"},{"key":"2026050515301343200_dkag156-B23","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1086\/505494","article-title":"Tigecycline: a critical analysis","volume":"43","author":"Stein","year":"2006","journal-title":"Clin Infect Dis"},{"key":"2026050515301343200_dkag156-B24","doi-asserted-by":"publisher","first-page":"175","DOI":"10.3109\/00365548.2013.861608","article-title":"Tigecycline therapy for infections due to carbapenemase-producing Klebsiella pneumoniae in critically ill patients","volume":"46","author":"Balandin Moreno","year":"2014","journal-title":"Scand J Infect Dis"}],"container-title":["Journal of Antimicrobial Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jac\/article-pdf\/81\/6\/dkag156\/68222362\/dkag156.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jac\/article-pdf\/81\/6\/dkag156\/68222362\/dkag156.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T19:30:17Z","timestamp":1778009417000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jac\/article\/doi\/10.1093\/jac\/dkag156\/8669877"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,5]]},"references-count":24,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,5,5]]}},"URL":"https:\/\/doi.org\/10.1093\/jac\/dkag156","relation":{},"ISSN":["0305-7453","1460-2091"],"issn-type":[{"value":"0305-7453","type":"print"},{"value":"1460-2091","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,6]]},"published":{"date-parts":[[2026,5,5]]},"article-number":"dkag156"}}